Dr. Ahrens-Nicklas works to understand why patients with inherited biochemical disorders often suffer severe, untreatable neurologic and cardiac symptoms. She strives to elucidate the link between biochemistry and network excitability, in order to drive new approaches to therapy.
Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.
Dr. Rubenstein's research focuses on basic and translational studies of novel means to improve outcomes in cystic fibrosis. He initially focused on correcting the dysfunction of mutant cystic fibrosis transmembrane conductance regulator (CFTR) proteins, which led him to study how molecular chaperones regulate the biogenesis and trafficking of CFTR and other proteins that are relevant to cystic fibrosis.
Dr. Douglas has extensive laboratory experience investigating the cellular immunology of HIV/AIDS, primary immune deficiency diseases, and cellular immunopathologies. In addition, he has had significant involvement in studies related to immunological interactions.
The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.
Dr. Gmuca seeks to enhance the care of children with chronic musculoskeletal pain. Her current research addresses amplified musculoskeletal pain syndrome, which is a major public health issue because of its high prevalence, related socioeconomic burden, and associated risk of opioid exposure. Dr. Gmuca’s work aims to identify innovative strategies to improve long-term treatment outcomes for this patient population.
Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.
Dr. Goldberg's research program focuses on investigating cerebral cortical circuit function and dysfunction in neurodevelopmental disorders. Using a variety of research techniques, Dr. Goldberg has a specific research interest in the workings of neuron subtype called GABAergic inhibitory interneuron and the role of interneuron dysfunction in disease.
Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.
Dr. Kenyon's research focuses on integrating care systems and reducing outcome disparities for children with asthma. His recent work focuses on developing novel interventions to enhance asthma controller medication use in the highest risk children by leveraging mobile health technology and incentives oriented to the child.